FR22C1062I2 - DOSE Escalation ENZYME REPLACEMENT THERAPY FOR THE TREATMENT OF ACID SPHINGOMYELINASE DEFICIENCY - Google Patents

DOSE Escalation ENZYME REPLACEMENT THERAPY FOR THE TREATMENT OF ACID SPHINGOMYELINASE DEFICIENCY

Info

Publication number
FR22C1062I2
FR22C1062I2 FR22C1062C FR22C1062C FR22C1062I2 FR 22C1062 I2 FR22C1062 I2 FR 22C1062I2 FR 22C1062 C FR22C1062 C FR 22C1062C FR 22C1062 C FR22C1062 C FR 22C1062C FR 22C1062 I2 FR22C1062 I2 FR 22C1062I2
Authority
FR
France
Prior art keywords
treatment
replacement therapy
dose escalation
enzyme replacement
acid sphingomyelinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR22C1062C
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Icahn School of Medicine at Mount Sinai
Original Assignee
Genzyme Corp
Icahn School of Medicine at Mount Sinai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43625265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR22C1062(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp, Icahn School of Medicine at Mount Sinai filed Critical Genzyme Corp
Publication of FR22C1062I1 publication Critical patent/FR22C1062I1/en
Application granted granted Critical
Publication of FR22C1062I2 publication Critical patent/FR22C1062I2/en
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Dermatology (AREA)
FR22C1062C 2009-08-28 2022-12-15 DOSE Escalation ENZYME REPLACEMENT THERAPY FOR THE TREATMENT OF ACID SPHINGOMYELINASE DEFICIENCY Active FR22C1062I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23811309P 2009-08-28 2009-08-28
EP10812683.0A EP2470199B1 (en) 2009-08-28 2010-08-28 Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
PCT/US2010/047057 WO2011025996A2 (en) 2009-08-28 2010-08-28 Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency

Publications (2)

Publication Number Publication Date
FR22C1062I1 FR22C1062I1 (en) 2023-02-03
FR22C1062I2 true FR22C1062I2 (en) 2023-12-29

Family

ID=43625265

Family Applications (1)

Application Number Title Priority Date Filing Date
FR22C1062C Active FR22C1062I2 (en) 2009-08-28 2022-12-15 DOSE Escalation ENZYME REPLACEMENT THERAPY FOR THE TREATMENT OF ACID SPHINGOMYELINASE DEFICIENCY

Country Status (27)

Country Link
US (9) US8349319B2 (en)
EP (3) EP3998078A1 (en)
JP (7) JP5955219B2 (en)
KR (5) KR20230164773A (en)
CN (3) CN105999238A (en)
AU (5) AU2010286550B2 (en)
BR (1) BR112012004377A2 (en)
CA (1) CA2773133A1 (en)
CL (1) CL2012000495A1 (en)
CY (1) CY1122128T1 (en)
DK (2) DK2470199T3 (en)
ES (2) ES2738859T3 (en)
FR (1) FR22C1062I2 (en)
HR (2) HRP20211992T1 (en)
HU (3) HUE057440T2 (en)
IL (4) IL300625B1 (en)
LT (2) LT2470199T (en)
MX (1) MX356873B (en)
NL (1) NL301211I2 (en)
NO (1) NO2022054I1 (en)
PL (2) PL3482767T3 (en)
PT (2) PT3482767T (en)
RU (3) RU2731616C2 (en)
SI (2) SI3482767T1 (en)
TR (1) TR201911293T4 (en)
WO (1) WO2011025996A2 (en)
ZA (2) ZA201201435B (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006007560A2 (en) 2004-07-01 2006-01-19 University Of Pennsylvania Targeted protein replacement for the treatment of lysosomal storage disorders
US20080228056A1 (en) 2007-03-13 2008-09-18 Michael Blomquist Basal rate testing using frequent blood glucose input
US7751907B2 (en) 2007-05-24 2010-07-06 Smiths Medical Asd, Inc. Expert system for insulin pump therapy
US8221345B2 (en) 2007-05-30 2012-07-17 Smiths Medical Asd, Inc. Insulin pump based expert system
PL3252161T3 (en) 2007-06-06 2022-03-07 Genzyme Corporation Gene therapy for lysosomal storage diseases
KR20230164773A (en) * 2009-08-28 2023-12-04 이칸 스쿨 오브 메디슨 엣 마운트 시나이 Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
US8882701B2 (en) * 2009-12-04 2014-11-11 Smiths Medical Asd, Inc. Advanced step therapy delivery for an ambulatory infusion pump and system
CA2798812A1 (en) 2010-05-21 2011-11-24 Ohmx Corporation Detection of cancer by assaying psa enzymatic activity
RU2645675C2 (en) 2011-03-18 2018-02-27 Джензим Корпорейшн Glucosylceramide-synthase inhibitors
EP3741384A1 (en) 2011-09-07 2020-11-25 Mount Sinai School Of Medicine Ceramidase and cell differentiation
JP6243846B2 (en) 2011-11-15 2017-12-06 セントジーン アーゲー Methods for diagnosis of Neiman-Pick disease
WO2013181530A1 (en) 2012-06-01 2013-12-05 Icahn School Of Medicine At Mount Sinai Ceramide levels in the treatment and prevention of infections
JOP20130273B1 (en) 2012-09-11 2021-08-17 Genzyme Corp Glucosylceramide synthase inhibitors
PL2968479T3 (en) 2013-03-14 2019-10-31 Icahn School Med Mount Sinai Therapeutic acid ceramidase compositions and methods of making and using them
JO3713B1 (en) 2013-03-15 2021-01-31 Genzyme Corp SALT FORMS OF (S)-Quinuclidin-3-yl (2-(2-(4-fluorophenyl)thiazol-4-yl)propan-2-yl)carbamate
TR201906195T4 (en) * 2013-05-14 2019-05-21 Centogene Ag Method for diagnosing Niemann pick disease.
US10022428B2 (en) * 2013-06-07 2018-07-17 Genzyme Corporation Marker for acid sphingomyelinase disorders and uses thereof
JP6984854B2 (en) * 2015-10-08 2021-12-22 国立大学法人千葉大学 Pharmaceutical composition for preventing or treating Niemann-Pick disease type C
US10569016B2 (en) 2015-12-29 2020-02-25 Tandem Diabetes Care, Inc. System and method for switching between closed loop and open loop control of an ambulatory infusion pump
EP3672622B1 (en) 2017-08-24 2023-11-08 Genzyme Corporation Recombinant human acid sphingomyelinase for use in treating abnormal bone conditions in acid sphingomyelinase deficiency patients
CR20200129A (en) 2017-10-02 2020-08-22 Denali Therapeutics Inc Fusion proteins comprising enzyme replacement therapy enzymes
UY38238A (en) 2018-05-25 2019-12-31 Genzyme Corp PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF ACID SPHINGOMYELINASE DEFICIENCY
IL295255A (en) 2020-02-03 2022-10-01 Genzyme Corp Methods for treating neurological symptoms associated with lysosomal storage diseases
CA3186766A1 (en) 2020-07-24 2022-01-27 Danielle Combessis Pharmaceutical compositions comprising venglustat

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4039388A (en) 1976-06-04 1977-08-02 The United States Of America As Represented By The Government Diagnostic test for Niemann-Pick disease
US4082781A (en) 1976-06-04 1978-04-04 The United States Of America As Represented By The Department Of Health, Education And Welfare Synthesis of 2-alkanoylamino-4-nitrophenyl phosphorylcholine-hydroxide
IL74761A0 (en) 1984-04-13 1985-06-30 Hughes Howard Med Inst Human phenylalanine hydroxylase cdna clones,their production and their use in diagnosing classical phenylketonuria
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4863195A (en) * 1987-10-02 1989-09-05 Capozzola Carl A Identification tag
US5047335A (en) 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5549892A (en) 1988-12-23 1996-08-27 Genzyme Corporation Enhanced in vivo uptake of glucocerebrosidase
US5773278A (en) 1991-05-03 1998-06-30 Mount Sinai Medical Center Acid sphingomyelinase gene
US5612487A (en) 1991-08-26 1997-03-18 Edible Vaccines, Inc. Anti-viral vaccines expressed in plants
US6034298A (en) 1991-08-26 2000-03-07 Prodigene, Inc. Vaccines expressed in plants
US5484719A (en) 1991-08-26 1996-01-16 Edible Vaccines, Inc. Vaccines produced and administered through edible plants
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5716614A (en) 1994-08-05 1998-02-10 Molecular/Structural Biotechnologies, Inc. Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier
US5929304A (en) 1995-09-14 1999-07-27 Croptech Development Corporation Production of lysosomal enzymes in plant-based expression systems
JP2820106B2 (en) 1996-02-29 1998-11-05 日本電気株式会社 Traffic shaper device
US20050032211A1 (en) 1996-09-26 2005-02-10 Metabogal Ltd. Cell/tissue culturing device, system and method
IL155588A0 (en) 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
CN100410268C (en) 1998-12-23 2008-08-13 博伊斯汤普生植物研究所 Expression of immunogenic hepatitis B surface antigens in transgenic plants
US6642038B1 (en) 1999-09-14 2003-11-04 Genzyme Glycobiology Research Institute, Inc. GlcNAc phosphotransferase of the lysosomal targeting pathway
AU2001250856A1 (en) 2000-03-17 2001-10-03 Charles Arntzen Expression of recombinant human acetylcholinesterase in transgenic plants
WO2001097829A2 (en) * 2000-06-19 2001-12-27 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
AR034413A1 (en) 2000-08-25 2004-02-25 Nestor Abel Chamoles METHOD FOR DETERMINING THE ACTIVITY OF LISOSOMAL ENZYMES
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
US7001994B2 (en) 2001-01-18 2006-02-21 Genzyme Corporation Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteins
US7396811B2 (en) 2001-04-30 2008-07-08 Zystor Therapeutics, Inc. Subcellular targeting of therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
IES20011101A2 (en) * 2001-12-21 2003-06-25 Japkinstill Services Ltd A Bi-directional Messaging System
US7658916B2 (en) 2002-04-05 2010-02-09 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
US7585518B2 (en) 2002-11-19 2009-09-08 Kimberly-Clark Worldwide, Inc. Products and methods for maintaining or increasing ceramide levels in skin
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
CA2528427A1 (en) * 2003-06-12 2004-12-23 Genzyme Corporation Modified human acid sphingomyelinase having increased activity, and methods for making the same
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) * 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US7750050B2 (en) 2003-11-25 2010-07-06 Mount Sinai School Of Medicine Of New York University Chaperone-based therapy for Niemann-Pick disease
MX2007004414A (en) 2004-10-13 2007-09-25 Protalix Ltd System and method for production of antibodies in plant cell culture.
US7615224B2 (en) 2004-12-02 2009-11-10 Women's And Children's Hospital Multiplex-bead complex for determination of lysosomal storage disorders
AU2006333135A1 (en) 2005-12-15 2007-07-12 The Research Foundation Of State University Of New York Enzymatic methods for measuring plasma and tissue sphingomylelin and phosphatidylcholine
AR059089A1 (en) * 2006-01-20 2008-03-12 Genzyme Corp INTRAVENTRICULAR ADMINISTRATION OF AN ENZYME FOR LISOSOMAL STORAGE DISEASES
EP1981546B1 (en) 2006-02-06 2014-06-04 The Medical Research and Infrastructure Fund of the Tel-Aviv Sourasky Medical Center Enzyme replacement therapy for treating lysosomal storage diseases
DK1988823T3 (en) 2006-02-09 2018-12-03 Genzyme Corp SLOW INTRAVENTRICULAR ADMINISTRATION
JP2009526526A (en) 2006-02-13 2009-07-23 フラウンホーファー ユーエスエー， インコーポレイテッド Influenza antigens, vaccine compositions, and related methods
JP5302189B2 (en) 2007-04-27 2013-10-02 長瀬産業株式会社 Sphingomyelinase
US20110237538A1 (en) 2008-08-06 2011-09-29 Summit Corporation Plc Treatment of lysosomal storage disorders and other proteostatic diseases
BR122020010601B8 (en) 2008-12-16 2021-07-27 Genzyme Corp protein-oligosaccharide conjugates, their uses, and pharmaceutical compositions
KR20230164773A (en) * 2009-08-28 2023-12-04 이칸 스쿨 오브 메디슨 엣 마운트 시나이 Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
EP2721151B1 (en) * 2011-06-20 2017-12-06 Mount Sinai School Of Medicine Anti-tnf-therapy for the mucopolysaccharidoses and other lysosomal disorders
US10022428B2 (en) * 2013-06-07 2018-07-17 Genzyme Corporation Marker for acid sphingomyelinase disorders and uses thereof
EP3672622B1 (en) * 2017-08-24 2023-11-08 Genzyme Corporation Recombinant human acid sphingomyelinase for use in treating abnormal bone conditions in acid sphingomyelinase deficiency patients

Also Published As

Publication number Publication date
US20180055916A1 (en) 2018-03-01
ZA201601362B (en) 2017-05-31
WO2011025996A2 (en) 2011-03-03
AU2016216625A1 (en) 2016-09-15
DK2470199T3 (en) 2019-08-05
AU2016216625B2 (en) 2018-07-05
JP2023012499A (en) 2023-01-25
IL218324B (en) 2019-05-30
ES2902229T3 (en) 2022-03-25
NL301211I2 (en) 2023-02-02
ES2738859T3 (en) 2020-01-27
JP2020090513A (en) 2020-06-11
AU2020256322B2 (en) 2024-02-29
HUE046598T2 (en) 2020-03-30
JP7395693B2 (en) 2023-12-11
US8349319B2 (en) 2013-01-08
JP6251307B2 (en) 2017-12-20
CY1122128T1 (en) 2020-11-25
JP7167281B2 (en) 2022-11-08
RU2015145255A (en) 2019-01-11
US9655954B2 (en) 2017-05-23
EP2470199A2 (en) 2012-07-04
US20110052559A1 (en) 2011-03-03
KR102608551B1 (en) 2023-12-04
NL301211I1 (en) 2022-12-28
US20130078230A1 (en) 2013-03-28
NO2022054I1 (en) 2022-12-01
KR20120081077A (en) 2012-07-18
WO2011025996A9 (en) 2011-08-25
IL266915A (en) 2019-07-31
US20220305091A1 (en) 2022-09-29
US20130078231A1 (en) 2013-03-28
JP5955219B2 (en) 2016-07-20
CA2773133A1 (en) 2011-03-03
KR102094253B1 (en) 2020-03-31
SI2470199T1 (en) 2019-11-29
IL218324A0 (en) 2012-04-30
HRP20211992T1 (en) 2022-04-01
KR20210107153A (en) 2021-08-31
BR112012004377A2 (en) 2017-12-12
CN102596232A (en) 2012-07-18
RU2015145255A3 (en) 2019-08-12
JP2018076322A (en) 2018-05-17
KR102608546B1 (en) 2023-12-04
AU2010286550B2 (en) 2016-05-19
KR20200034828A (en) 2020-03-31
RU2020128994A (en) 2022-03-02
RU2012111823A (en) 2013-10-10
WO2011025996A3 (en) 2012-03-15
JP2016153408A (en) 2016-08-25
CN106047835A (en) 2016-10-26
CN105999238A (en) 2016-10-12
US20210077593A1 (en) 2021-03-18
PT3482767T (en) 2021-12-29
JP2013502933A (en) 2013-01-31
PT2470199T (en) 2019-08-07
PL3482767T3 (en) 2022-02-14
RU2569744C2 (en) 2015-11-27
LT2470199T (en) 2019-10-10
AU2018204156A1 (en) 2018-06-28
JP6952810B2 (en) 2021-10-20
EP2470199A4 (en) 2013-03-27
IL266915B2 (en) 2023-07-01
IL266915B1 (en) 2023-03-01
ZA201201435B (en) 2020-05-27
HRP20191385T1 (en) 2019-11-01
AU2024201085A1 (en) 2024-03-07
US20190151419A1 (en) 2019-05-23
RU2731616C2 (en) 2020-09-07
EP3482767A1 (en) 2019-05-15
AU2020256322A1 (en) 2020-11-12
SI3482767T1 (en) 2022-03-31
US9114139B2 (en) 2015-08-25
US20160120957A1 (en) 2016-05-05
IL300625B1 (en) 2024-09-01
MX2012002449A (en) 2012-03-14
US8658162B2 (en) 2014-02-25
AU2010286550A1 (en) 2012-03-15
EP2470199B1 (en) 2019-05-22
EP3998078A1 (en) 2022-05-18
KR20230164773A (en) 2023-12-04
TR201911293T4 (en) 2019-08-21
US8709408B2 (en) 2014-04-29
IL314807A (en) 2024-10-01
US20140335070A1 (en) 2014-11-13
HUE057440T2 (en) 2022-05-28
EP3482767B1 (en) 2021-10-06
MX356873B (en) 2018-06-18
DK3482767T3 (en) 2021-12-20
AU2018204156B2 (en) 2020-07-16
LT3482767T (en) 2022-01-10
CL2012000495A1 (en) 2014-02-07
JP2022003065A (en) 2022-01-11
KR20220104271A (en) 2022-07-26
US10188705B2 (en) 2019-01-29
PL2470199T3 (en) 2019-11-29
JP2024026214A (en) 2024-02-28
FR22C1062I1 (en) 2023-02-03
HUS2200050I1 (en) 2022-12-28
IL300625A (en) 2023-04-01

Similar Documents

Publication Publication Date Title
FR22C1062I2 (en) DOSE Escalation ENZYME REPLACEMENT THERAPY FOR THE TREATMENT OF ACID SPHINGOMYELINASE DEFICIENCY
HK1163500A1 (en) Pharmaceutical composition for the treatment of heart diseases
ZA201208535B (en) Formulations of quinones for the treatment of ophthalmic diseases
MX2022009942A (en) Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same.
IN2012DN06720A (en)
HK1186671A1 (en) Formulations for the treatment of disorders of the upper respiratory tract
IL260078B (en) Therapy for use for the treatment of gaucher's disease
FR20C1026I1 (en) CICLESONIDE FOR THE TREATMENT OF DISEASES OF THE RESPIRATORY TRACT IN HORSES
IL232384A (en) Use of the compounds halofenate or halofenic acid for the preparation of medicaments for treatment of gout
EP2398789A4 (en) Spiropyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease
FR2953723B1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ORTHOPEDIC DISEASES
IT1404270B1 (en) POSITIVE ALLGLASS MODULATORS OF MGLUR5 FOR USE AS MEDICATION IN THE THERAPEUTIC TREATMENT OF THE PHELAN-MCDERMID SYNDROME
FR2976807B1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DEPENDENCE IN HUMAN BEINGS
IT1397219B1 (en) PHARMACEUTICAL OR DIETETIC COMPOSITION FOR THE TREATMENT OF ATOPIA
FR2950619B1 (en) PROCESS FOR DEULFATATION OF ACID RELEASES FROM THE TITANIUM INDUSTRY
HK1157189A1 (en) Pharmaceutical composition for the treatment of tumor diseases
HU0800083D0 (en) Pharmaceutical compositions for the treatment and prevention of tumorous diseases
IL208127A0 (en) Ptph1 inhibitors for the treatment of alzheimer's disease